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Context: Early postmenopausal women with higher testosterone (T) levels have increased insulin
resistance (IR) and cardiovascular risk factors, but whether this translates into increased cardio-
vascular disease later in life is unknown.
Objective: The objective of the study was to determine whether higher T levels are associated with
IR, the metabolic syndrome (MetSyn), and coronary heart disease (CHD) in elderly women.
Design: Total T and free T by equilibrium dialysis were measured using ultrasensitive assays in 344
women aged 65–98 yr enrolled in the Cardiovascular Health Study. Cross-sectional analyses were
performed to examine the associations between total and free T and IR, MetSyn, and CHD.
Results: There was a stepwise increase in the homeostasis model assessment of insulin resistance with
increasing total (P  0.0.003) and free T (P  0.02) level and a corresponding decrease in Quantitative
Insulin Sensitivity Check Index (P  0.001 and P  0.002, respectively). In adjusted models, higher levels
ofbothtotalandfreeTwerestronglyassociatedwithabdominalobesityandhighfastingglucose, thetwo
MetSyn components most strongly linked to IR. After adjustment, women in the top quartile of total T
levels had a 3-fold greater odds of MetSyn (odds ratio 3.15, 95% confidence interval 1.57–6.35) than
those in the bottom quartile and a 3-fold greater odds of CHD (odds ratio 2.95, 95% confidence interval
1.2–7.3)thanthoseinsecondquartile,whereasfreeTwasnotsignificantlyassociatedwithMetSynorCHD.
Conclusions: Higher levels of T are associated with IR, MetSyn, and CHD in elderly women. Whether
T is a marker or mediator of cardiovascular disease in this population merits further investigation.
(J Clin Endocrinol Metab 94: 4776–4784, 2009)
The clinical relevance of testosterone (T) in women overthe age of 65 yr is unknown. Many premenopausal
women with polycystic ovary syndrome (PCOS) have hy-
perandrogenism and insulin resistance (IR), and numer-
ous studies have demonstrated a high prevalence of car-
diovascular risk factors and the metabolic syndrome
(MetSyn) in these women (1). Additional studies in peri-
and early postmenopausal women without a known his-
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tory of PCOS have shown that women with higher levels
of T are more likely to have IR, MetSyn, and cardiovas-
cular disease (CVD) (2–11).
The potential link between higher levels of T and IR has
not been extensively examined in elderly women, the
group of women with the highest prevalence of MetSyn
and the greatest cardiovascular risk (12, 13). Using data
from the Cardiovascular Health Study (CHS), we have
previously shown that levels of T are significantly lower in
women aged 65 yr and older than in a reference population
of younger women but that the same factors that nega-
tively affect the production of T in younger women (bi-
lateral oophorectomy, estrogen use, and corticosteroid
use) also are associated with lower levels of T in women
aged 65 yr and older (14). These data suggest that a pop-
ulation shift in T levels occurs with age and that the as-
sociation between T and cardiovascular risk factors found
in younger populations of women should track into later
life. However, it is also possible that there is a threshold
relationship between T and these factors and that the
lower levels found in older women are biologically irrel-
evant. Finally, it is also possible that the association be-
tween T and IR in these older women is similar to that in
older men, in whom lower T levels are associated with a
greater incidence of MetSyn and CVD (15–18). Our hy-
pothesis is consistent with the first of these scenarios, that
women aged 65 yr and older with higher total and free T
levels are more insulin resistant, have a greater prevalence




The CHS is a population-based, longitudinal study of risk
factors for developing CVDs in 5888 adults aged 65 yr and older
(19). Enrollment of an original cohort of 5201 adults occurred
between May 1989 and June 1990 and an additional cohort of
687 predominantly African-Americans enrolled in 1992–1993.
Eligible individuals were identified from an age- and gender-
stratified random sample of the Medicare eligibility rosters in
four U.S. communities: Washington County, MD; Pittsburgh,
PA; Sacramento County, CA; and Forsyth County, NC. To be
eligible, individuals had to be noninstitutionalized, expecting to
remain in the area for the following 3 yr, not under active cancer
treatment, not wheelchair bound in the home, not requiring a
proxy respondent at entry, and capable of providing consent.
Household members of the sampled individuals were recruited if
eligible. The institutional review boards of all four sites and the
coordinating center at the University of Washington (Seattle,
WA) approved the study, and all participants gave informed
consent.
These analyses are based on data from a random sample of
368 women seen at the 1992–1993 visit. This assessment in-
cluded a detailed medical history, physical examination, and
assessment of health status. Blood was drawn in the morning
after a 12-h fast and serum was frozen in 70 C freezers for
future investigations (20).
Of 368 women in the original sample, six women were ex-
cluded due to insufficient serum for analyzing free T and three
extreme outliers were excluded. Nine women taking oral corti-
costeroids were excluded due to their extremely low T values
(14), as were six other women with incomplete data on covari-
ates, yielding 344 subjects for analysis.
Assessment of biochemical measures
Total T concentrations were measured by RIA using iodin-
ated T as a tracer (21). This assay was developed and validated
for the low range of T prevalent in HIV-infected (21–23) and
postmenopausal women (24). The sensitivity, defined as hor-
mone concentration corresponding to 90% percent bound in
presence and absence of analyte point, was 0.22 ng/dl (0.008
nmol/liter). The intraassay coefficient of variation (CV) was
8.2%. Interassay CVs were measured in the low, medium, and
high female pool and were 13.2% in the medium pool. In other
pools, interassay CVs ranged from 13 to 15%. This assay was
validated against liquid chromatography-tandem mass spec-
trometry (23). These measurements demonstrated a correlation
of 0.997 between the RIA and liquid chromatography-tandem
mass spectrometry measurements. Free T concentrations were
measured by a sensitive equilibrium dialysis assay (21), opti-
mized to precisely and accurately measure low concentrations.
The sensitivity of this assay is 0.3 pg/ml (1.0 pmol/liter). Ten
replicates of low, medium, and high female pools were used to
generate intra- and interassay CVs. The respective intraassay
CVs for the low, medium, and high female pools were 5.6% for
the low pool, 4.6% for the medium pool, and 2.6% for the high
pool (21). The interassay CVs were in the 12–15% range. Cross-
reactivity of the major steroids (dehydroepiandrosterone, dehy-
droepiandrosterone sulfate, dihydrotestosterone, and andro-
stenedione) was less than 1%.
Fasting glucose levels were performed on the Kodak Ek-
tachem 700 Analyzer (Eastman Kodak Corp., Rochester, NY).
Fasting serum insulin was measured by solid-phase RIA, using
serum-based standards (Diagnostic Products Corp., Los Ange-
les, CA). As previously described (20), fasting total cholesterol,
high-density lipoprotein (HDL) cholesterol, and triglycerides
were measured directly and standardized according to Centers
for Disease Control and Prevention guidelines, with low-density
lipoprotein (LDL) cholesterol calculated according to the Friede-
wald equation (25).
Assessment of covariates
Sociodemographic characteristics included age, race, the
number of ovaries removed, and estrogen use. Medication use
was determined from examination of medication bottles at the
time of the study visit. Blood pressure was determined by the
average of duplicate measurements of sitting blood pressure eval-
uated in the right arm after a 5-min rest. Diabetes was defined as
a fasting glucose of 126 mg/dl or greater, 2-h postload glucose of
200 mg/dl or greater, medical history of diabetes, or use of insulin
or an oral hypoglycemic medication. Hypertension was defined
as systolic blood pressure of 140 mm Hg or greater, diastolic
blood pressure of 90 mm Hg or greater, or taking one or more
antihypertensive medications.
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Ascertainment of outcomes
Insulin resistance was assessed via calculation of homeostasis
model assessment insulin resistance (HOMA-IR): (fasting glu-
cose in milligrams per deciliter  insulin in microunits per mil-
liliter)/405 (26) and insulin sensitivity by calculation of the
Quantitative Insulin Sensitivity Check Index (QUICKI): 1/(log-
[fasting glucose in milligrams per deciliter]  log [insulin in mi-
crounits per milliliter]) (27).
As initially detailed in the National Cholesterol Education
Program Adult Treatment Panel III report (28) and later modi-
fied (29), women with three or more of the following criteria
were categorized as having the MetSyn: abdominal obesity
(waist circumference  88 cm); hypertriglyceridemia (fasting
triglycerides  150 mg/dl); low HDL cholesterol (HDL  50
mg/dl); high blood pressure (blood pressure  130/85 mm Hg or
using antihypertensive medication); and high fasting glucose
(also known as impaired fasting glucose; fasting glucose  100
mg or using antidiabetic medication).
Prevalent coronary heart disease (CHD) was defined by the
occurrence of angina, myocardial infarction, coronary angio-
plasty, or coronary artery bypass graft surgery occurring before
the blood draw from which T was measured. Provisional diag-
noses of CHD were reviewed and adjudicated at periodic meet-
ings of the study’s morbidity and mortality subcommittee, in-
cluding investigators from each field center and the coordinating
center. The full details of the surveillance and ascertainment of
events in CHS have been published previously (30).
Statistical analysis
For analytic purposes, T levels were categorized into quar-
tiles. Quartiles were selected for two reasons: there is no ref-
erence range for T levels in older women to define high levels,
and we wanted to allow for the possibility of a nonlinear
relationship. For total T, quartile (Q) 1 was 7.0 ng/dl or less,
Q2 was 7.1–15.0 ng/dl, Q3 was 15.1–27.0 ng/dl, and Q4 was
27.0 ng/dl or greater. For free T, Q1 was 1.4 pg/ml or less, Q2
was 1.5–2.0 pg/ml, Q3 was 2.1–3.2 pg/ml, and Q4 was 3.3
pg/ml or greater.
Median HOMA and QUICKI measurements were calculated
by quartile of total and free T level, and a trend test was per-
formed to assess statistical significance. Women using insulin or
with glucose greater than 200 mg/dl were excluded, yielding 328
women for inclusion in these analyses.
Total and free T levels were compared between women with
MetSyn and women without MetSyn in the entire group of 344
women as well as between women with and without each of the
individual MetSyn criteria. Student t tests were performed to
assess the association between log-transformed total and free T
levels and the presence or absence of MetSyn. The prevalence of
MetSyn and each of its components were also examined by quar-
tile of T and free T. Age, race, estrogen use, and bilateral ovarian
removal, factors that were previously found to be important
determinants of total and free T levels in women in this cohort
(14), were included in multivariable logistic regression models of
total and free T quartiles predicting MetSyn and each of its com-
ponents. All analyses were initially performed in the total sample
and were subsequently repeated excluding women with diabetes
mellitus.
Multivariable logistic regression models of total and free T
quartiles predicting CHD were adjusted for age, race, smoking,
estrogen use, hypertension, and LDL cholesterol. Additional
models including log HOMA-IR were performed.
All analyses were performed using SAS (version 8.2; SAS In-
stitute, Cary, NC).
Results
The 344 women ranged in age from 65 to 98 yr, with a
mean age of 74.4 yr (Table 1). The mean body mass index
(BMI) in our study cohort was 26.9 kg/m2. Nineteen per-
cent were current oral estrogen users. Thirteen percent had
diabetes and 30% had impaired fasting glucose. Forty-five
percent of our sample met the National Cholesterol Edu-
cation Program criteria for the MetSyn. Mean total tes-
tosterone levels were 19.1 ng/dl (range 1–133 ng/dl) and
mean free testosterone levels were 2.8 pg/ml (range 0.3–
20.6 pg/ml).
IR
With increasing total and free T levels, there was a step-
wise increase in IR, as assessed by HOMA-IR (P  0.003
and P  0.02, respectively; Fig. 1A). Likewise, there was
a stepwise decrease in insulin sensitivity, as assessed by
QUICKI, by quartile of total and free T (P  0.001 and P 
0.002, respectively; Fig. 1B).
TABLE 1. Selected characteristics of the study sample
(n  344)
Variable
Age (yr) 74.4 (5.1)
Education (yr) 14.6 (4.0)
White (%) 84
Bilateral oophorectomy (%) 17
BMI (kg/m2) 26.9 (5.3)
Current estrogen use (%) 19
Current smoking (%) 11
Total cholesterol (md/dl) 217 (39)
LDL cholesterol (mg/dl) 131 (37)
HDL cholesterol (mg/dl) 59 (15)
Triglycerides (mg/dl) 137 (71)
Total T (ng/dl) 19.1 (17.6)
Free T (pg/ml) 2.8 (2.5)
Fasting glucose (mg/dl) 107 (35)
Fasting insulin (IU/ml) 13 (15)
Diabetes (%)
Nondiabetic 57
Impaired fasting glucose 30
Diabetes 13
Systolic blood pressure (mm Hg) 136 (21)




Low HDL cholesterol 29
High blood pressure 68
High fasting glucose 13
Data are presented as mean (SD) unless otherwise indicated.
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MetSyn
For each criterion, as well as for MetSyn as a whole,
total T levels were higher in women in whom the criterion
was present compared with those in whom it was absent,
reaching statistical significance for all except hypertension
(Fig. 2A). A similar pattern was present for free T, al-
though the differences in free T levels between those with
and without the criterion were of smaller magnitude than
those seen for total T (Fig. 2B). Free T levels were signif-
icantly higher in women with MetSyn and in those with the
individual components of abdominal obesity, low HDL,
and high fasting glucose, but free T levels were not signif-
icantly different between those with hypertriglyceridemia
or hypertension and those without these two conditions.
The findings for total and free T persisted after exclusion
of the 43 women with diabetes.
When we examined the prevalence of the MetSyn by
quartile of total T levels, we found a strong relationship
between total T levels and MetSyn in crude (P  0.001)
and adjusted (P  0.007) models (Table 2). The relation-
ship was similar at lower levels (Q1 and Q2) of total T,
with a stepwise effect at higher levels (Q3 and Q4).
Women in the top quartile of total T levels had a 3-fold
greater odds of MetSyn than those in the bottom quartile
[adjusted odds ratio (OR) 3.15; confidence interval (CI)
1.57–6.35], an effect that persisted after additional ad-
justment for BMI (adjusted OR 2.81; CI 1.32–5.98).
Women in the top quartile of total T were also more
likely to have each of the criteria of MetSyn than those in
the bottom quartile, although the magnitude of these as-
sociations varied considerably and was not statistically
significant for the high blood pressure criterion (Table 2).
In adjusted models, the strongest associations were for
high fasting glucose (OR 5.93; CI 2.78–12.6) and abdom-
inal obesity (OR 3.65; CI 1.68–7.93), comparing Q4 with
Q1, with additional associations seen for low HDL (OR
2.29; 1.02–5.11) and hypertriglyceridemia (OR 2.19; CI
1.03–4.64).
After exclusion of women with diabetes, the relation-
ship between total T and MetSyn persisted, with a 3-fold
greater odds of the metabolic syndrome in women with
total T levels in Q4 vs. Q1 (adjusted OR 2.89; CI 1.36–
6.16) (Table 3). Of note, the group of women with high
fasting glucose in this set of analyses represents exclusively
women with impaired fasting glucose. Women in the top
two quartiles of total T levels were very likely to have
impaired fasting glucose (OR 4.95; CI 2.18–11.26 for Q4
vs. Q1; OR 2.77; CI 1.27–6.07 for Q3 vs.Q1). Likewise,
women in the top two quartiles of total T were more likely
to have abdominal obesity (OR 3.46; CI 1.52–7.87 for Q4































FIG. 1. A, Median HOMA-IR by quartile of total and free T. B, Median
QUICKI by total and free T quartiles. Higher HOMA-IR indicates greater
insulin resistance, whereas higher QUICKI indicates greater insulin
sensitivity. Women using insulin or with glucose greater than 200 mg/
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FIG. 2. A, Median total T levels in women with and without MetSyn.
B, Median free T levels in women with and without MetSyn. Abd Ob,
Abdominal obesity (waist circumference  88 cm); HyperTG,
hypertriglyceridemia (fasting triglycerides  150 mg/dl); low HDL
(HDL cholesterol  50 mg/dl); high BP, high blood pressure (blood
pressure  130/85 mm Hg or using antihypertensive medication); high
Glu, high fasting glucose (fasting glucose  100 mg or using
antidiabetic medication). Multiply by 0.0347 to convert total T
concentrations from nanograms per deciliter to nanomoles per liter.
Multiply by 3.47 to convert free T concentrations from picograms per
milliliter to picomoles per liter. *, P  0.05; **, P  0.01;
***, P  0.001.
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In comparison, free T was not statistically signifi-
cantly associated with MetSyn (adjusted OR 1.48; CI
0.75–2.91). However, free T levels were associated with
the components of MetSyn that are most closely linked to
IR: high fasting glucose (adjusted OR 2.37; CI 1.17–4.79)
and abdominal obesity (adjusted OR 2.23; CI 1.08–4.61),
comparing Q4 with Q1 (Table 2). These effects were at-
tenuated after exclusion of women with diabetes, achiev-
ing statistical significance in the crude but not the adjusted
analyses (Table 3).
CHD
A nonlinear, or J-shaped, relationship described the as-
sociation of total T and CHD (Table 4). For ease of in-
terpretation, Q2 was used as the reference category.
Women in the top quartile of total T had a 3-fold greater
odds of CHD compared with those in the reference cate-
gory, independent of sociodemographic and traditional
cardiovascular risk factors (Q4 vs. Q2 OR 2.95, CI 1.2–
7.3). Free T was not associated with CHD. Adjusting for
HOMA-IR decreased the magnitude of the multivariable-
adjusted OR for the association between the top quartile
of total T and CHD by 20% (from 2.95 to 2.35) but min-
imally affected the association between the top quartile of
free T and CHD (from 1.41 to 1.37).
Discussion
In a cohort of women aged 65 yr and older, we demon-
strated strong associations between total and free T levels
and IR as well as components of MetSyn that are more
closely tied to IR (high fasting glucose and abdominal obe-
sity). Higher total T levels were also independently asso-
ciated with hypertriglyceridemia, low HDL cholesterol,
MetSyn, and prevalent CHD, although these associations
were not found with free T.
Our findings suggest that even at the physiologically
low levels of T found in these older women, the association
between T and IR found in perimenopausal and early post-
menopausal women (2, 5–11) persists into old age. In this
cross-sectional study, we could not determine the direc-
tion of causality of this relationship. Data from premeno-
pausal women with PCOS suggest that the effect is largely
TABLE 2. Odds ratios of MetSyn components and MetSyn by T quartile for the entire sample (n  344)










Q1 1.0 1.0 1.0 1.0
Q2 0.98 (0.53, 1.81) 0.92 (0.47, 1.80) 1.34 (0.72, 2.50) 1.25 (0.65, 2.40)
Q3 2.11 (1.11, 3.99) 2.01 (1.00, 4.05) 1.81 (0.95, 3.43) 1.56 (0.78, 3.12)
Q4 4.26 (2.08, 8.73) 3.65 (1.68, 7.93) 2.70 (1.38, 5.30) 2.23 (1.08, 4.61)
Hypertriglyceridemia
Q1 1.0 1.0 1.0 1.0
Q2 1.22 (0.61, 2.43) 1.26 (0.60, 2.63) 0.98 (0.50, 1.91) 0.96 (0.48, 1.92)
Q3 1.57 (0.80, 3.09) 1.85 (0.89, 3.86) 1.12 (0.58, 2.17) 1.09 (0.53, 2.23)
Q4 1.95 (0.99, 3.82) 2.19 (1.03, 4.64) 1.30 (0.67, 2.52) 1.52 (0.74, 3.13)
Low HDL cholesterol
Q1 1.0 1.0 1.0 1.0
Q2 1.21 (0.55, 2.67) 0.82 (0.36, 1.90) 1.02 (0.49, 2.14) 0.86 (0.39, 1.89)
Q3 2.67 (1.28, 5.56) 2.00 (0.91, 4.40) 1.81 (0.89, 3.66) 1.35 (0.63, 2.93)
Q4 3.46 (1.66, 7.20) 2.29 (1.02, 5.11) 2.10 (1.04, 4.24) 1.82 (0.84, 3.95)
High blood pressure
Q1 1.0 1.0 1.0 1.0
Q2 0.80 (0.42, 1.53) 0.76 (0.38, 1.53) 0.72 (0.37, 1.38) 0.60 (0.30, 1.20)
Q3 0.93 (0.48, 1.77) 0.81 (0.40, 1.64) 0.84 (0.43, 1.64) 0.72 (0.35, 1.48)
Q4 1.41 (0.71, 2.80) 1.28 (0.60, 2.73) 1.04 (0.52, 2.06) 0.80 (0.38, 1.68)
High fasting glucose
Q1 1.0 1.0 1.0 1.0
Q2 1.69 (0.83, 3.45) 1.47 (0.70, 3.09) 1.40 (0.72, 2.71) 1.28 (0.64, 2.54)
Q3 3.38 (1.70, 6.72) 2.90 (1.40, 6.01) 2.08 (0.84, 4.64) 1.77 (0.88, 3.56)
Q4 7.13 (3.52, 14.45) 5.93 (2.78, 12.63) 3.05 (1.59, 8.27) 2.37 (1.17, 4.79)
Adult Treatment Panel III MetSyn
Q1 1.0 1.0 1.0 1.0
Q2 0.83 (0.43, 1.60) 0.71 (0.35, 1.41) 0.90 (0.48, 1.68) 0.79 (0.41, 1.51)
Q3 2.09 (1.11, 3.92) 1.81 (0.92, 3.54) 1.33 (0.71, 2.48) 1.09 (0.56, 2.13)
Q4 3.87 (2.02, 7.42) 3.15 (1.57, 6.35) 1.86 (0.99, 3.50) 1.48 (0.75, 2.91)
Adjusted models included age, race, estrogen use, and number of ovaries removed. Statistically significant values are indicated in bold.
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a stimulatory effect of hyperinsulinemia on ovarian an-
drogen production, although a few studies suggest that
testosterone may worsen insulin resistance (31). We are
aware of only two studies that examined aspects of the
T-IR relationship in study populations of women with a
similar mean age to ours. The Invecchiare nel CHIANTI
Study reported that older women with MetSyn had higher
bioavailable T, but not total T levels, and that neither
measure of T was associated with MetSyn in adjusted
models (32). Both T measures were assessed in linear mod-
els that did not allow for the threshold effects we saw in
our study. In the Rancho Bernardo Study, bioavailable T
levels were associated with fasting plasma glucose and
were higher in women with impaired glucose tolerance or
type 2 diabetes (33). Differences in results between these
two studies and ours may in part reflect differences in
assay methodology, mean BMI (lowest in the Rancho Ber-
nardo Study and similar between inCHIANTI and CHS),
and exclusion criteria (estrogen users were excluded in
both inCHIANTI and the Rancho Bernardo Study, and,
additionally, women with bilateral oophorectomy were
excluded from the inCHIANTI analyses). The mecha-
TABLE 4. Odds ratios of CHD by total T and free T quartiles for the entire sample










Q1 2.12 (0.8, 5.4) 2.12 (0.8, 5.7) 1.23 (0.5, 2.9) 1.19 (0.5, 2.8)
Q2 1.0 1.0 1.0 1.0
Q3 1.38 (0.5, 3.6) 1.26 (0.5, 3.4) 0.85 (0.4, 2.0) 0.87 (0.4, 2.1)
Q4 3.17 (1.3, 7.6) 2.95 (1.2, 7.3) 1.47 (0.7, 3.2) 1.41 (0.6, 3.2)
Adjusted models included age, race, smoking, estrogen use, hypertension, and LDL cholesterol. Statistically significant values are indicated in bold.
TABLE 3. Odds ratios of MetSyn components and MetSyn by testosterone quartile for those without diabetes (n  301)










Q1 1.0 1.0 1.0 1.0
Q2 0.92 (0.49, 1.74) 0.93 (0.47, 1.86) 1.19 (0.62, 2.26) 1.13 (0.58, 2.22)
Q3 2.06 (1.06, 3.99) 2.10 (1.02, 4.33) 1.81 (0.93, 3.54) 1.63 (0.79, 3.33)
Q4 3.82 (1.78, 8.19) 3.46 (1.52, 7.87) 2.39 (1.17, 4.85) 2.05 (0.96, 4.39)
Hypertriglyceridemia
Q1 1.0 1.0 1.0 1.0
Q2 1.13 (0.56, 2.30) 1.20 (0.56, 2.55) 0.89 (0.44, 1.77) 0.91 (0.44, 1.86)
Q3 1.53 (0.76, 3.06) 1.87 (0.88, 3.98) 1.09 (0.55, 2.16) 1.08 (0.52, 2.26)
Q4 1.74 (0.85, 3.56) 1.96 (0.88, 4.33) 1.09 (0.54, 2.22) 1.27 (0.59, 2.73)
Low HDL cholesterol
Q1 1.0 1.0 1.0 1.0
Q2 1.00 (0.44, 2.27) 0.68 (0.29, 1.65) 0.89 (0.41, 1.91) 0.76 (0.34, 1.72)
Q3 1.99 (0.93, 4.28) 1.50 (0.66, 3.40) 1.25 (0.60, 2.64) 0.89 (0.40, 2.01)
Q4 3.01 (1.39, 6.53) 1.97 (0.85, 4.61) 1.70 (0.80, 3.58) 1.40 (0.62, 3.17)
High blood pressure
Q1 1.0 1.0 1.0 1.0
Q2 0.84 (0.43, 1.63) 0.80 (0.39, 1.65) 0.76 (0.39, 1.51) 0.65 (0.32, 1.33)
Q3 0.87 (0.45, 1.69) 0.79 (0.38, 1.63) 0.73 (0.37, 1.45) 0.63 (0.30, 1.33)
Q4 1.29 (0.63, 2.66) 1.26 (0.57, 2.78) 0.98 (0.47, 2.00) 0.80 (0.37, 1.74)
High fasting glucose
Q1 1.0 1.0 1.0 1.0
Q2 1.54 (0.70, 3.35) 1.44 (0.64, 3.24) 1.18 (0.58, 2.40) 1.08 (0.52, 2.45)
Q3 3.07 (1.45, 6.48) 2.77 (1.27, 6.07) 1.70 (0.84, 3.44) 1.48 (0.71, 3.11)
Q4 5.50 (2.55, 11.89) 4.95 (2.18, 11.26) 2.21 (1.08, 4.52) 1.80 (0.85, 3.84)
Adult Treatment Panel III MetSyn
Q1 1.0 1.0 1.0 1.0
Q2 0.82 (0.41, 1.65 0.72 (0.34, 1.52) 0.85 (0.44, 1.66) 0.78 (0.39, 1.54)
Q3 1.87 (0.96, 3.65) 1.74 (0.86, 3.54) 1.10 (0.57, 2.14) 0.93 (0.46, 1.89)
Q4 3.30 (1.64, 6.65) 2.89 (1.36, 6.16) 1.53 (0.78, 3.00) 1.29 (0.63, 2.67)
Adjusted models included age, race, estrogen use, and number of ovaries removed. Statistically significant values are indicated in bold.
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nisms that contribute to the T-IR relationship bear further
investigation in older women, in light of the increase in
visceral adiposity and resultant IR with increasing age (34)
and the sustained ability of the ovary to produce testos-
terone after menopause (35).
Although MetSyn was highly prevalent among the par-
ticipants in our study, at 45%, and has been widely studied
as a risk factor for cardiovascular disease, our analyses of
the individual MetSyn criteria suggest that the primary
determinant of the relationship between T and MetSyn is
IR, even after exclusion of women with diabetes. We do
not know the menstrual histories of these women, and
their premenopausal years preceded the first definition of
PCOS. However, our analyses suggest that our findings
are not solely confined to women with a prior history of
PCOS, given a greater than 2-fold higher prevalence of
abdominal obesity and high fasting glucose in women in
the top 50% of T levels, compared with the bottom 25%.
Studies examining the relationship between endoge-
nous T levels and CVD in postmenopausal women have
yielded conflicting results. Several studies suggest that
higher T levels are protective against CVD (36–38); how-
ever, these studies examined an early postmenopausal
population when the prevalence of CVD is low. The Ran-
cho Bernardo Study found no association between T and
fatal CVD, although this study population had relatively
low BMI values (39). On the other hand, three studies
found that higher T levels are associated with increased
CVD (3, 10, 40).
We found a J-shaped relationship between total T and
CHD. Those in the bottom and top quartiles were more
likely to have had a greater odds of CHD compared with
those in the second quartile, although only the top quartile
association was statistically significant. It is possible that
those in the bottom quartile had lower T levels because of
systemic underlying illness, although we did not specifi-
cally test this. Another possibility is that there is a target
range of acceptable T levels and that both too little and too
much have negative consequences. Interestingly, data in
men have consistently shown that lower T levels are as-
sociated with increased CVD risk factors (41, 42), CVD
(17, 18), and CVD mortality (43), suggesting a gender
dimorphism.
In our study, the associations between T and MetSyn
and CHD were universally stronger for total T than for
free T. We do not have SHBG levels in our study popula-
tion, but there are two potential explanations for our find-
ings. The most likely explanation is that our free T assay,
which was performed by equilibrium dialysis, had diffi-
culty discriminating among the low levels found in these
women, introducing additional noise into our data anal-
yses. Alternatively, these data suggest that the increase in
T had a predominant effect over the expected decrease in
SHBG seen with high insulin levels in the setting of IR, and
this may have contributed to the weaker association of free
T levels with our outcomes.
The strengths of our study include its population-based
sample of older women; the measurement of each of the
Adult Treatment Panel III criteria for MetSyn; the rigorous
definition of diabetes, which included an oral glucose tol-
erance test in those without known diabetes; the use of an
adjudicated CHD outcome; and the use of highly sensitive
assays. However, our analyses are cross-sectional in na-
ture, which limits causal inference. Residual confounding
is also possible despite adjustment for multiple potential
confounders.
Although our study extends the finding of a T-IR rela-
tionship to a population of women of advanced age, the
clinical implications of this finding are unclear. The ma-
jority of mechanistic studies performed in premenopausal
women with PCOS suggest that T is simply a marker of IR
(44). However, several studies support the potential for
adverse effects of T on IR (31). If so, then augmented T
concentrations could be an additional contributor to the
age-related increase in risk of metabolic disorders in post-
menopausal women. Further studies are required to de-
termine whether a causal relationship exists between tes-
tosterone and IR and to provide more insight into the role
T plays in the pathogenesis of CVD in women.
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